- Kiadis Pharma floated on Euronext Amsterdam and Euronext Brussels
- Proceeds of the IPO will be used to advance the clinical development of the lead products
- Kempen & Co acted as Sole Global Coordinator and Joint Bookrunner in the transaction
At Kempen.com, we use cookies to improve the quality of our website and service.
The investment services and investment institutions mentioned on the website may not be available in your jurisdiction or to anyone other than professional investors. More information about the countries where these investment institutions are registered and the persons to whom they may be offered can be found on the website.
Click here to view our Privacy Policy.
